Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication / 감염과화학요법
Infection and Chemotherapy
;
: 396-402, 2020.
Artigo
| WPRIM
| ID: wpr-834281
ABSTRACT
There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak.We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio 0.111, 95% confidence interval 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Revista:
Infection and Chemotherapy
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS